REFERENCES
1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75:74-84.
2. Ljungberg B, Albiges L, Bedke J. EAU guidelines on renal cell carcinoma. Available from: https://uroweb.org/guideline/renal-cell-carcinoma/ [Last accessed on 14 Sep 2021].
3. Rühle A, Andratschke N, Siva S, Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 2019;18:104-12.
4. Frick MA, Chhabra AM, Lin L, Simone CB 2nd. First ever use of proton stereotactic body radiation therapy delivered with curative intent to bilateral synchronous primary renal cell carcinomas. Cureus 2017;9:e1799.
5. Correa RJ, Louie AV, Zaorsky NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus 2019;5:958-69.
6. De Meerleer G, Khoo V, Escudier B, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 2014;15:e170-7.
7. Sathishkumar S, Boyanovsky B, Karakashian AA, et al. Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis. Cancer Biol Ther 2005;4:979-86.
8. Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 2017;14:549-63.
9. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015;41:503-10.
10. Tselis N, Chatzikonstantinou G. Treating the Chameleon: radiotherapy in the management of Renal Cell Cancer. Clin Transl Radiat Oncol 2019;16:7-14.
11. Ingrosso G, Becherini C, Francolini G, et al. Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. Crit Rev Oncol Hematol 2021;159:103242.
12. Siva S, Correa RJM, Warner A, et al. Stereotactic ablative radiotherapy for ≥T1b primary renal cell carcinoma: a report from the international radiosurgery oncology consortium for kidney (IROCK). Int J Radiat Oncol Biol Phys 2020;108:941-9.
13. Correa RJM, Ahmad B, Warner A, et al. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma. Radiat Oncol 2018;13:47.
14. Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. Urology 2009;73:1077-82.
15. Siva S, Jackson P, Kron T, et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship. Radiother Oncol 2016;118:540-6.
16. Devos G, Berghen C, Van Eecke H, et al. Oncological outcomes of metastasis-directed therapy in oligorecurrent prostate cancer patients following radical prostatectomy. Cancers (Basel) 2020;12:2271.
17. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011;117:2873-82.
18. Yang JC, Abad J, Sherry R. Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol 2006;16:131-5.
19. Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 2009;96:579-92.
20. Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011;185:439-44.
21. Russo AE, Untch BR, Kris MG, et al. Adrenal metastasectomy in the presence and absence of extraadrenal metastatic disease. Ann Surg 2019;270:373-7.
22. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J Urol 2000;164:1505-8.
23. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007;89:1794-801.
24. Higuchi T, Yamamoto N, Hayashi K, et al. Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. Bone Joint J 2018;100-B:1241-8.
25. Vickers MM, Al-Harbi H, Choueiri TK, et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013;11:311-5.
26. Stief C, Hagemann J, Kuczyk M, Jonas U. Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol 1997;158:375-7.
27. Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 2003;10:705-10.
28. Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncol 2014;10:761-74.
29. Franzese C, Franceschini D, Di Brina L, et al. Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J Urol 2019;201:70-6.
30. Cochran DC, Chan MD, Aklilu M, et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 2012;116:978-83.
31. Stenman M, Sinclair G, Paavola P, Wersäll P, Harmenberg U, Lindskog M. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiother Oncol 2018;127:501-6.
32. Svedman C, Sandström P, Pisa P, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006;45:870-5.
33. Meyer E, Pasquier D, Bernadou G, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group. Eur J Cancer 2018;98:38-47.
34. Marvaso G, Corrao G, Oneta O, et al. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol 2021;23:1717-26.
35. Kano H, Iyer A, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases. Neurosurgery 2011;69:1232-9.
36. Singh R, Ansinelli H, Sharma D, et al. Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: a multi-institutional experience. J Radiosurg SBRT 2020;7:29-37.
37. Ranck MC, Golden DW, Corbin KS, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol 2013;36:589-95.
38. Wersäll PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005;77:88-95.
39. Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012;82:1744-8.
40. Ikushima H, Tokuuye K, Sumi M, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2000;48:1389-93.
41. Gundem G, Van Loo P, Kremeyer B, et al. ICGC Prostate Group. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353-7.
42. Berghen C, Joniau S, Vulsteke C, et al. Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancermedicalscience 2020;14:1036.
43. Mohamad O, Sishc BJ, Saha J, et al. Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an emphasis on DNA damage/repair. Cancers (Basel) 2017;9:66.
44. Malouff TD, Mahajan A, Krishnan S, Beltran C, Seneviratne DS, Trifiletti DM. Carbon Ion Therapy: a modern review of an emerging technology. Front Oncol 2020;10:82.
45. Gergelis KR, Jethwa KR, Tryggestad EJ, Ashman JB, Haddock MG, Hallemeier CL. Proton beam radiotherapy for esophagus cancer: state of the art. J Thorac Dis 2020;12:7002-10.
46. Fukumitsu N, Ishikawa H, Arimura T, et al. Proton therapy for primary renal cell carcinoma: the first nationwide retrospective study in Japan. In Vivo 2020;34:2883-9.
47. Baydoun A, Vapiwala N, Ponsky LE, et al. Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning. J Appl Clin Med Phys 2018;19:125-30.
48. Thompson A, Ding X, Abbott V, et al. Proton stereotactic body radiotherapy as a nephron-sparing approach for patients with localized renal cell carcinoma: a dosimetric analysis. Int J Radiat Oncol 2019;105:E713.
49. Nomiya T, Tsuji H, Hirasawa N, et al. Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience. Int J Radiat Oncol Biol Phys 2008;72:828-33.
50. Kasuya G, Tsuji H, Nomiya T, et al. Working Group for Genitourinary Tumors. Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma. Cancer Sci 2018;109:2873-80.
51. Kasuya G, Tsuji H, Nomiya T, et al. Working Group for Genitourinary Tumors. Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma. Oncotarget 2019;10:76-81.
52. Nakao HT. A case of lung and lymphnode metastasis treated with carbon ion radiotherapy after radical nephrectomy for renal cell carcinoma. Hinyokika Kiyo 2008;54:345-7.
53. Rief H, Chaudhri N, Tonndorf-Martini E, et al. Intensity-modulated radiotherapy versus proton radiotherapy versus carbon ion radiotherapy for spinal bone metastases: a treatment planning study. J Appl Clin Med Phys 2015;16:186-194.
54. Macewan I, Chou B, Mifflin R, Wroe A, Bush D. Passively scattered proton stereotactic body radiation therapy for spine metastasis: a dosimetric analysis. Int J Radiat Oncol 2016;96:E675-6.
55. Loeffler JS, Durante M. Charged particle therapy-optimization, challenges and future directions. Nat Rev Clin Oncol 2013;10:411-24.
56. Ruysscher D, Sterpin E, Haustermans K, Depuydt T. Tumour movement in proton therapy: solutions and remaining questions: a review. Cancers (Basel) 2015;7:1143-53.
58. Buti G, Souris K, Montero AMB, Lee JA, Sterpin E. Towards fast and robust 4D optimization for moving tumors with scanned proton therapy. Med Phys 2019;46:5434-43.
